The World Health Organization (WHO) has prequalified an additional novel oral polio vaccine type 2 (nOPV2), further strengthening the global supply of a vaccine at the heart of efforts to stop poliovirus type 2 outbreaks more sustainably and accelerate progress towards polio eradication.
The prequalification designation indicates that the vaccine meets international standards of quality, safety, and efficacy for global immunization programmes. It enables the vaccine to be purchased and supplied through United Nations procurement agencies, including UNICEF, supporting its use across multiple country settings for the prevention and control of poliovirus transmission.
The newly prequalified product is manufactured by Biological E. Limited (BioE), India, using in-house bulk vaccine following a technology transfer from PT Bio Farma (Persero), Indonesia. This prequalification builds on earlier WHO listings of nOPV2 manufactured by PT Bio Farma, as well as the vaccine formulated and filled by BioE using bulk supplied by PT Bio Farma.
For further information, follow the News link below: